Does the media favor ALNY or EXEL?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 9 mentions for Exelixis. Alnylam Pharmaceuticals' average media sentiment score of 0.92 beat Exelixis' score of 0.59 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, EXEL or BIIB?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.38B 5.80 $782.57M $3.01 18.20 Biogen $9.89B 3.22 $1.29B $9.32 23.18

Is EXEL or BIIB more profitable?

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.08% 39.89% 30.23% Biogen 13.81% 12.83% 8.01%

Does the media prefer EXEL or BIIB?

In the previous week, Biogen had 2 more articles in the media than Exelixis. MarketBeat recorded 11 mentions for Biogen and 9 mentions for Exelixis. Biogen's average media sentiment score of 0.78 beat Exelixis' score of 0.59 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EXEL or UTHR?

In the previous week, United Therapeutics had 8 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for United Therapeutics and 9 mentions for Exelixis. United Therapeutics' average media sentiment score of 0.80 beat Exelixis' score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, INCY or EXEL?

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.42 $1.29B $7.08 16.07 Exelixis $2.38B 5.80 $782.57M $3.01 18.20

Is INCY or EXEL more profitable?

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 26.71% 26.66% 19.77% Exelixis 35.08% 39.89% 30.23%

Does the media refer more to INCY or EXEL?

In the previous week, Incyte had 8 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for Incyte and 9 mentions for Exelixis. Incyte's average media sentiment score of 0.69 beat Exelixis' score of 0.59 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer EXEL or NBIX?

In the previous week, Exelixis had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.27 beat Exelixis' score of 0.59 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Neurocrine Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$54.77 +1.54 (+2.89%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$54.90 +0.13 (+0.24%)

As of 06/26/2026 06:31 PM Eastern

Compare

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Exelixis stock or one of its competitors? MarketBeat compares Exelixis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Exelixis has a net margin of 35.08% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Exelixis	35.08%	39.89%	30.23%

Alnylam Pharmaceuticals currently has a consensus price target of $463.13, suggesting a potential upside of 58.95%. Exelixis has a consensus price target of $46.87, suggesting a potential downside of 14.43%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Exelixis	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Alnylam Pharmaceuticals and 9 mentions for Exelixis. Alnylam Pharmaceuticals' average media sentiment score of 0.92 beat Exelixis' score of 0.59 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	10.47	$313.75M	$3.66	79.61
Exelixis	$2.38B	5.80	$782.57M	$3.01	18.20

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats Exelixis on 12 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.80	$782.57M	$3.01	18.20
Biogen	$9.89B	3.22	$1.29B	$9.32	23.18

Exelixis currently has a consensus target price of $46.87, indicating a potential downside of 14.43%. Biogen has a consensus target price of $217.37, indicating a potential upside of 0.62%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30
Biogen	1 Sell rating(s)	12 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.57

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Biogen	13.81%	12.83%	8.01%

In the previous week, Biogen had 2 more articles in the media than Exelixis. MarketBeat recorded 11 mentions for Biogen and 9 mentions for Exelixis. Biogen's average media sentiment score of 0.78 beat Exelixis' score of 0.59 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Biogen beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to United Therapeutics?

Exelixis (NASDAQ:EXEL) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

United Therapeutics has a net margin of 40.62% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
United Therapeutics	40.62%	19.24%	17.25%

United Therapeutics has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.80	$782.57M	$3.01	18.20
United Therapeutics	$3.18B	7.24	$1.33B	$27.09	20.03

Exelixis has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, United Therapeutics had 8 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for United Therapeutics and 9 mentions for Exelixis. United Therapeutics' average media sentiment score of 0.80 beat Exelixis' score of 0.59 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis currently has a consensus price target of $46.87, suggesting a potential downside of 14.43%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 14.14%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe United Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

United Therapeutics beats Exelixis on 14 of the 16 factors compared between the two stocks.

How does Exelixis compare to Incyte?

Incyte (NASDAQ:INCY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Exelixis	35.08%	39.89%	30.23%

Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.42	$1.29B	$7.08	16.07
Exelixis	$2.38B	5.80	$782.57M	$3.01	18.20

In the previous week, Incyte had 8 more articles in the media than Exelixis. MarketBeat recorded 17 mentions for Incyte and 9 mentions for Exelixis. Incyte's average media sentiment score of 0.69 beat Exelixis' score of 0.59 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

97.0% of Incyte shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Incyte presently has a consensus target price of $107.85, suggesting a potential downside of 5.19%. Exelixis has a consensus target price of $46.87, suggesting a potential downside of 14.43%. Given Incyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Incyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Exelixis	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

Incyte beats Exelixis on 10 of the 15 factors compared between the two stocks.

How does Exelixis compare to Neurocrine Biosciences?

Exelixis (NASDAQ:EXEL) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Exelixis has higher earnings, but lower revenue than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.80	$782.57M	$3.01	18.20
Neurocrine Biosciences	$2.86B	5.92	$478.60M	$6.49	25.97

In the previous week, Exelixis had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 9 mentions for Exelixis and 6 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.27 beat Exelixis' score of 0.59 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Neurocrine Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exelixis has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Exelixis presently has a consensus price target of $46.87, indicating a potential downside of 14.43%. Neurocrine Biosciences has a consensus price target of $187.52, indicating a potential upside of 11.28%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Summary

Neurocrine Biosciences beats Exelixis on 11 of the 17 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.38B	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	18.20	21.56	25.82	24.18
Price / Sales	5.80	334.04	576.05	114.38
Price / Cash	17.58	137.38	46.99	54.37
Price / Book	6.80	8.34	10.77	6.36
Net Income	$782.57M	$23.91M	$3.58B	$337.99M
7 Day Performance	5.51%	3.42%	2.20%	0.10%
1 Month Performance	9.47%	1.55%	1.11%	-0.11%
1 Year Performance	25.42%	65.22%	34.26%	27.60%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.233 of 5 stars	$54.77 +2.9%	$46.87 -14.4%	+27.1%	$13.38B	$2.38B	18.20	1,077	Analyst Forecast High Trading Volume
ALNY Alnylam Pharmaceuticals	4.1613 of 5 stars	$281.90 -2.1%	$463.13 +64.3%	-8.4%	$37.64B	$4.29B	77.02	2,770
BIIB Biogen	3.0402 of 5 stars	$195.52 -1.6%	$216.70 +10.8%	+70.2%	$28.87B	$9.94B	20.98	7,500
UTHR United Therapeutics	4.4937 of 5 stars	$548.27 -0.2%	$619.42 +13.0%	+91.0%	$23.27B	$3.18B	20.24	1,400	Insider Trade
INCY Incyte	3.6217 of 5 stars	$99.75 -2.2%	$105.10 +5.4%	+60.6%	$19.93B	$5.14B	14.09	2,844	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to United Therapeutics?

Summary

How does Exelixis compare to Incyte?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Is ALNY or EXEL more profitable?

Do analysts rate ALNY or EXEL?

Does the media favor ALNY or EXEL?

Which has higher earnings & valuation, ALNY or EXEL?

Do institutionals and insiders hold more shares of ALNY or EXEL?

Which has more volatility & risk, ALNY or EXEL?

Summary

How does Exelixis compare to Biogen?

Which has better earnings and valuation, EXEL or BIIB?

Do analysts rate EXEL or BIIB?

Is EXEL or BIIB more profitable?

Does the media prefer EXEL or BIIB?

Which has more risk and volatility, EXEL or BIIB?

Do institutionals & insiders believe in EXEL or BIIB?

Summary

How does Exelixis compare to United Therapeutics?

Is EXEL or UTHR more profitable?

Which has better earnings & valuation, EXEL or UTHR?

Which has more volatility & risk, EXEL or UTHR?

Do insiders & institutionals believe in EXEL or UTHR?

Does the media prefer EXEL or UTHR?

Do analysts recommend EXEL or UTHR?

Summary

How does Exelixis compare to Incyte?

Is INCY or EXEL more profitable?

Which has more volatility & risk, INCY or EXEL?

Which has better valuation and earnings, INCY or EXEL?

Does the media refer more to INCY or EXEL?

Do insiders and institutionals believe in INCY or EXEL?

Do analysts rate INCY or EXEL?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Which has preferable valuation and earnings, EXEL or NBIX?

Does the media prefer EXEL or NBIX?

Do institutionals & insiders believe in EXEL or NBIX?

Which has more risk & volatility, EXEL or NBIX?

Do analysts prefer EXEL or NBIX?

Is EXEL or NBIX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools